BioCardia CEO Altman Peter Buys 700 Shares at $1.83/Share on 2023-08-22.
PorAinvest
lunes, 25 de agosto de 2025, 12:05 pm ET1 min de lectura
BCDA--
The filing details the transaction, noting that the shares were acquired directly, with the total purchase amounting to $1,284.40. The transaction was executed in multiple trades, with prices ranging from $1.82 to $1.89 per share. The reported price reflects the weighted average per share sales price.
This insider trading activity, as reported, is significant for investors as it provides insights into the company's leadership's confidence in its current financial position and future prospects. The purchase of shares by a high-ranking executive like Altman can often be seen as a positive indicator, suggesting that the executive believes in the company's long-term growth potential.
Investors should closely monitor future developments and earnings reports from BioCardia, Inc. to assess the impact of this transaction on the company's financial performance and stock price.
References:
[1] https://www.stocktitan.net/sec-filings/BCDAW/form-4-bio-cardia-inc-warrant-insider-trading-activity-7e3cd17c8a32.html
BioCardia, Inc. (BCDA) has recently announced that Director, President, and CEO Peter Altman has purchased 700 shares at a price of $1.83 per share on August 22, 2025.
BioCardia, Inc. (BCDA) has recently announced that its Director, President, and CEO, Peter Altman, has purchased 700 shares of the company's common stock. The transaction took place on August 22, 2025, at a price of $1.83 per share. This purchase was reported to the U.S. Securities and Exchange Commission (SEC) through a Form 4 filing [1].The filing details the transaction, noting that the shares were acquired directly, with the total purchase amounting to $1,284.40. The transaction was executed in multiple trades, with prices ranging from $1.82 to $1.89 per share. The reported price reflects the weighted average per share sales price.
This insider trading activity, as reported, is significant for investors as it provides insights into the company's leadership's confidence in its current financial position and future prospects. The purchase of shares by a high-ranking executive like Altman can often be seen as a positive indicator, suggesting that the executive believes in the company's long-term growth potential.
Investors should closely monitor future developments and earnings reports from BioCardia, Inc. to assess the impact of this transaction on the company's financial performance and stock price.
References:
[1] https://www.stocktitan.net/sec-filings/BCDAW/form-4-bio-cardia-inc-warrant-insider-trading-activity-7e3cd17c8a32.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios